Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

Phase 2AK146D1IvonescimabPositive

AI Analysis

Summary

Akeso announced first patient dosing in Phase II study (AK146D1-202) evaluating its TROP2/Nectin-4 bispecific antibody-drug conjugate AK146D1 combined with Ivonescimab in breast cancer, advancing its IO2.0 + ADC2.0 strategy.

Clinical Trial Data

Phase

Phase II

Outcome Details

First patient dosed in Phase II study (AK146D1-202)

Importance:6/10

Sentiment:

0.60

Bispecific ADCCombination TherapyIO2.0ADC2.0TROP2Nectin-4Breast Cancer

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on August 10, 2026 4:05 AM

Read Original